Ascentage Pharma Group International Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG0519B1023
HKD
52.05
0.05 (0.1%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%

  • Poor long term growth as Operating profit has grown by an annual rate -18.51% of over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
  • NET SALES(Q) At HKD 251.03 MM has Fallen at -71.88%
  • DEBTORS TURNOVER RATIO(HY) Lowest at 0.95 times
  • PRE-TAX PROFIT(Q) Lowest at HKD -660.77 MM
2

Risky -

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

HKD 17,718 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.06

stock-summary
Return on Equity

-175.87%

stock-summary
Price to Book

24.28

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.26%
0%
2.26%
6 Months
-33.61%
0%
-33.61%
1 Year
13.4%
0%
13.4%
2 Years
185.68%
0%
185.68%
3 Years
132.89%
0%
132.89%
4 Years
224.5%
0%
224.5%
5 Years
56.54%
0%
56.54%

Ascentage Pharma Group International Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
91.26%
EBIT Growth (5y)
-18.51%
EBIT to Interest (avg)
-39.31
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.57
Sales to Capital Employed (avg)
0.15
Tax Ratio
2.64%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
103.00
EV to EBIT
-71.51
EV to EBITDA
-94.80
EV to Capital Employed
40.63
EV to Sales
27.66
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-56.81%
ROE (Latest)
-156.72%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Ascentage Pharma Group International Co., Ltd."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 333.43% vs 0.57% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 57.00% vs 0.37% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,063.20",
          "val2": "245.30",
          "chgp": "333.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-309.70",
          "val2": "-900.20",
          "chgp": "65.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "69.90",
          "val2": "106.10",
          "chgp": "-34.12%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "2.30",
          "chgp": "-86.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-439.80",
          "val2": "-1,022.90",
          "chgp": "57.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-386.30%",
          "val2": "-4,018.30%",
          "chgp": "363.20%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
1,063.20
245.30
333.43%
Operating Profit (PBDIT) excl Other Income
-309.70
-900.20
65.60%
Interest
69.90
106.10
-34.12%
Exceptional Items
0.30
2.30
-86.96%
Consolidate Net Profit
-439.80
-1,022.90
57.00%
Operating Profit Margin (Excl OI)
-386.30%
-4,018.30%
363.20%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 333.43% vs 0.57% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 57.00% vs 0.37% in Dec 2023

stock-summaryCompany CV
About Ascentage Pharma Group International Co., Ltd. stock-summary
stock-summary
Ascentage Pharma Group International Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available